I would say that we’re making progress in terms of engaging consumers in quality of care, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.
I would say that we’re making progress in terms of engaging consumers in quality of care, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.
Transcript
How engaged are consumers in quality efforts and how can we better engage patients?
I would say that we’re making progress in terms of engaging consumers in quality of care, and of course when we talk about quality of care, I think we think about a variety of different dimensions. There's what the outcome is for the patient, pending what clinical circumstance or procedure that they need. Knee replacement is a very specific example of, you want to be functional again, you want to be relieved of pain, you want to be able to sort of get back to doing things that you can do, so forth and so on.
There’s also just the general patient experience and satisfaction with the healthcare system itself, which may include things like being involved in treatment decisions and sort of shared decision making. And then, of course, there’s the cost of care. So, I think in terms of what’s really pushed, a little bit, the involvement of patients is, the move toward high-deductible health plans in more additional first dollar out-of-pocket costs coming out of patients’ pockets.
I don’t want to pretend that its pervasive, that people are shopping around like they are for consumer goods, like autos or refrigerators. But, I do think that more first dollar coverage, for better for worse, has led people to think about what the cost implications are, as well as the quality implications, the overall value equation for decisions that they’re going to make. There are some pretty good tools available, but the evidence still suggests those tools are not used as much as we would like them to be used. And, we still very much live in a system where referrals from friends and family, going where your doctor refers you to. You know, “this is a good orthopod, I suggest you have your surgery done here.”
Often times, one of the challenges too, is that by the time you get into care and you’re being referred for specialty care, you’re already in a system of care and yes, you have the ability with broad plan choice to go outside of that, but it’s very difficult when you’re kind of already working with a primary care physician or family physician who’s referring you to the specialist. So, I think we are making progress, but it’s slow, and I suspect that we’ll continue to make more progress in that area.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More